0001213900-24-021213.txt : 20240311 0001213900-24-021213.hdr.sgml : 20240311 20240311070316 ACCESSION NUMBER: 0001213900-24-021213 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 24736524 BUSINESS ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 8-K 1 ea0201449-8k_180life.htm CURRENT REPORT
false 0001690080 0001690080 2024-03-07 2024-03-07 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-03-07 2024-03-07 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 7, 2024

 

180 LIFE SCIENCES CORP.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38105   90-1890354
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

   94306
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 507-0669

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ATNF   The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock   ATNFW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b) Resignation of Director

 

On March 7, 2023, Sir Marc Feldmann, Ph.D. provided notice to the Board of Directors of 180 Life Sciences Corp. (the “Company”, “we” and “us”) of his resignation as a member of the Board of Directors, effective on the same date (March 7, 2024). Sir Feldmann’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices, or otherwise.

 

Prior to his resignation, Sir Feldmann served as Co-Executive Chairman of the Company, but did not serve on any committees of the Board of Directors. Sir Feldmann will continue to serve as an employee of one of the Company’s subsidiaries.

 

(d) Appointment of New Directors

 

Effective March 7, 2024, the Board of Directors of the Company appointed Omar Jimenez and Ryan L. Smith (collectively, the “Appointees” and the “Appointments”) as members of the Board of Directors (“Board”), which Appointments were effective as of the same date. Mr. Jimenez and Mr. Smith were each appointed as a Class II director, and will serve until the Company’s 2024 Annual Meeting of Stockholders, until their successors have been duly elected and qualified, or until their earlier death, resignation or removal.

 

At the same time, the Board, pursuant to the power provided to the Board by the Company’s Second Amended and Restated Certificate of Incorporation, as amended, set the number of members of the Board at five (5) members.

 

The Board of Directors determined that each of Messrs. Jimenez and Smith were “independent” pursuant to the rules of the Nasdaq Capital Market and pursuant to Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, and that Mr. Jimenez will be considered the Company’s “audit committee financial expert” pursuant to Section (a)(5) of Item 407 of Regulation S-K.

 

Messrs. Jimenez and Smith are not party to any material plan, contract or arrangement (whether or not written) with the Company, except for the Offer Letters (discussed and described below), and there are no arrangements or understandings between Messrs. Jimenez and Smith and any other person pursuant to which Messrs. Jimenez or Smith were selected to serve as a director of the Company, nor are Messrs. Jimenez or Smith a participant in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.

 

The Company plans to enter into a standard form of Indemnity Agreement (the “Indemnification Agreement”) with Messrs. Jimenez and Smith in connection with their appointments to the Board. The Indemnification Agreement provides, among other things, that the Company will indemnify Messrs. Jimenez and Smith under the circumstances and to the extent provided for therein, for certain expenses they may be required to pay in connection with certain claims to which they may be made a party by reason of their position as directors of the Company, and otherwise to the fullest extent permitted under Delaware law and the Company’s governing documents. The foregoing is only a brief description of the Indemnification Agreement, does not purport to be complete and is qualified in its entirety by the Company’s standard form of indemnification agreement, previously filed as Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (No. 333-217475), as amended, on April 26, 2017. The Indemnification Agreement will be identical in all material respects to the indemnification agreements entered into with other Company directors.

 

There are no family relationships between any director or executive officer of the Company, including Messrs. Jimenez and Smith.

 

1

 

 

Also on March 7, 2024, the Board determined to combine the Strategy and Alternatives Committee and the Risk, Safety and Regulatory Committee into a Strategy and Alternatives, Risk, Safety and Regulatory Committee, which has materially the same responsibilities that the two committees had prior to such combination.

 

Upon his appointment to the Board, Mr. Jimenez was appointed as a member of the Board’s (a) Compensation Committee; (c) Nominating and Corporate Governance Committee; and (c) Strategy and Alternatives, Risk, Safety and Regulatory Committee, and as Chairperson of the Company’s Audit Committee.

 

Upon his appointment to the Board, Mr. Smith was appointed as a member of the Board’s (a) Audit Committee; and (b) Strategy and Alternatives, Risk, Safety and Regulatory Committee, and as Chairperson of the Compensation Committee and Nominating and Corporate Governance Committee.

 

As a result, the Committees of the Board of Directors are currently as follows:

 

Director Name  Audit
Committee		  Compensation
Committee		 

Nominating,
Corporate Governance
Committee

  Strategy and
Alternatives,
Risk, Safety
and Regulatory
Committee
Lawrence Steinman, M.D. (1)           
James N. Woody, M.D., Ph.D.            
Blair Jordan (2)  M  M  M  C
Omar Jimenez  C  M  M  M
Ryan Smith  M  C  C  M

 

(1) Executive Chairman of the Board of Directors.

 

(2) Lead Independent Director.

 

C - Chairperson of the Committee.

 

M - Member of the Committee.

 

In connection with Messrs. Jimenez and Smith’s appointments to the Board and on March 4, 2024 and March 5, 2024, respectively, to be effective upon each of their appointments to the Board, the Company entered into an offer letter with each of Messrs. Jimenez and Smith (collectively, the “Offer Letters”). The Offer Letters provide for each of Messrs. Jimenez and Smith to be paid $40,000 per year as an annual retainer fee for serving on the Board; Mr. Jimenez to be paid $10,000 per year for serving as the Chairman of the Audit Committee; and Mr. Smith to be paid $10,000 per year for serving as the Chairman of the Compensation Committee and Nominating and Corporate Governance Committee. The Company agreed to pay each of Messrs. Jimenez and Smith in connection with their appointment to the Board, quarterly in arrears, and pro-rated for partial quarters. Messrs. Jimenez and Smith have the option of receiving half of their compensation in cash and half of their compensation in stock, or alternatively receiving all of their compensation in cash, with half of such cash compensation accrued until such time as the Company raises an aggregate of $1 million from any source (for greater certainty, such sources being cumulative and not discrete), including but not limited to debt and/or equity raises, quasi- equity raises, receipt of insurance proceeds, litigation proceeds, and corporate transactions.

 

The foregoing summary of the material terms of the Offer Letters is not complete and is qualified in its entirety by reference to the Offer Letters, copies of which are filed herewith as Exhibits 10.1 and 10.2, and incorporated by reference in this Item 5.02.

 

2

 

 

Biographical information for Messrs. Jimenez and Smith is provided below:

 

Omar Jimenez, age 62

 

Mr. Jimenez has served as Chief Financial Officer (Principal Financial/Accounting Officer) and Chief Compliance Officer of Golden Matrix Group, Inc. (GMGI:NASDAQ), an established business-to-business and business-to-consumer gaming technology company operating across multiple international markets, since April 2021. Since February 2020, Mr. Jimenez has also served as Chief Financial Officer and Chief Operating Officer of Alfadan, Inc. a pre-startup that will provide a series of marine specific engines ranging from 450 horsepower (HP) to 1,050 HP when the research and development on such engines is completed. From September 2016 to January 2020 and from January 2016 to January 2020, Mr. Jimenez served as Treasurer and Secretary and Chief Financial Officer and Chief Operating Officer, respectively, of NextPlay Technologies, Inc. (f/k/a Monaker Group, Inc.) (NXTP:NASDAQ), a travel services company. Mr. Jimenez also served as a member of the Board of Directors of NextPlay Technologies, Inc. (then known as Monaker Group, Inc.) from January 2017 to August 2019. Mr. Jimenez has held a variety of senior financial management positions during his career. From May 2009 to January 2016, he served as the founder of MARMEL International, Inc., a company that provides accounting and consulting services. In addition, from June 2004 to May 2009 he served as President and Chief Financial Officer at American Leisure Holdings, Inc. (AMLH:OTC & ALG:AIM), focusing on leisure and business travel, hospitality & hotels, call centers and real estate development. Mr. Jimenez also served from April 2002 to June 2004 as Director of Operations for US Installation Group, Inc., a selling and installation group for The Home Depot, and CFO and VP of Onyx Group, Inc., a conglomerate with 700 employees and annual revenues exceeding $400 million. Mr. Jimenez is a Certified Public Accountant (CPA), Chartered Global Management Accountant (CGMA), Chartered Property Casualty Underwriter (CPCU), a Member of the AICPA and FICPA. Mr. Jimenez holds a B.B.A in Accounting and a B.B.A in Finance from the University of Miami and an M.B.A from Florida International University.

 

We have concluded that Mr. Jimenez is well qualified to serve on our Board of Directors based upon his significant business and accounting experience, including his public company background and his knowledge in compliance matters.

 

Ryan L. Smith, Age 41

 

Since December 2019, Mr. Smith has served as Chief Executive Officer of U.S. Energy Corp. (USEG:NASDAQ)(“U.S. Energy”), an oil and gas company focused on consolidating high-quality producing assets in the United States. Mr. Smith served as Chief Financial Officer of U.S. Energy from May 2017 to June 2023, and has served as a member of the Board of Directors of U.S. Energy since January 2021. Mr. Smith consulted for U.S. Energy from January 2017 to May 2017. Prior to holding that position, Mr. Smith served as Emerald Oil Inc.’s Chief Financial Officer from September 2014 to January 2017 and Vice President of Capital Markets and Strategy from July 2013 to September 2014. Emerald Oil Inc. filed for Chapter 11 bankruptcy protection in March 2016 and emerged from bankruptcy in November 2016. Prior to joining Emerald, Mr. Smith was a Vice President in Canaccord Genuity’s Investment Banking Group focused solely on the energy sector. Mr. Smith joined Canaccord Genuity in 2008 and was responsible for the execution of public and private financing engagements along with mergers and acquisitions advisory services. Prior to joining Canaccord Genuity, Mr. Smith was an Analyst in the Wells Fargo Energy Group, working solely with upstream and midstream oil and gas companies. Mr. Smith holds a Bachelor of Business Administration degree in Finance from Texas A&M University.

 

We have concluded that Mr. Smith is well qualified to serve on our Board of Directors based upon his significant business experience, including his public company background, and experience in public company fund raising.

 

* * * * *

 

As a result of the resignation from the Board of Directors of Sir Feldmann (who was not independent), and the appointment of Messrs. Jimenez and Smith to the Board of Directors, as of March 7, 2024, the Company now has a Board of Directors consisting of a majority of independent members (as determined by the rules of Nasdaq), and an Audit Committee; Compensation Committee; and Nominating and Corporate Governance Committee, each consisting of three independent members.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
     
10.1*   Offer Letter between 180 Life Science Corp. and Omar Jimenez (director) dated March 4, 2024 and effective March 7, 2024
10.2*   Offer Letter between 180 Life Science Corp. and Ryan L. Smith (director) dated March 5, 2024 and effective March 7, 2024
104   Inline XBRL for the cover page of this Current Report on Form 8-K

 

* Filed herewith.

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  180 LIFE SCIENCES CORP.
     
Date: March 11, 2024 By:  /s/ James N. Woody, M.D., Ph.D.
    James N. Woody, M.D., Ph.D.
    Chief Executive Officer

 

4

 EX-10.1 2 ea020144901ex10-1_180life.htm OFFER LETTER BETWEEN 180 LIFE SCIENCE CORP. AND OMAR JIMENEZ (DIRECTOR) DATED MARCH 4, 2024 AND EFFECTIVE MARCH 7, 2024

Exhibit 10.1

 

 

March 4, 2024

 

Dear Omar:

 

On behalf of 180 Life Sciences Corp., a Delaware corporation (the “Company”), I am pleased to extend to you an offer to join the Company’s Board of Directors (the “Board”), effective upon approval of your appointment by the Board of Directors. This offer is contingent upon (i) your completion of the enclosed Officers, Directors, Managers and Principal Stockholders Questionnaire and Supplemental Questionnaire for Director Nominees, (ii) receipt of a background check satisfactory to the Company, (iii) your confirmation of the enclosed Policy on Insider Trading and Policy on Control and Disclosure of Confidential Information, and (iv) formal approval of your appointment by the Board.

 

The Company’s current schedule includes approximately four regular meetings of the Board, which are currently held via Zoom, plus additional special meetings as called by the Board from time to time which usually take place via Zoom. In addition to your attendance at Board meetings, we expect to take advantage of your expertise by reaching out to you for advice and counsel between meetings. To the extent that you are appointed as a member of the Audit Committee, you will need to meet at least quarterly with the other members of the committee. It is anticipated that you will serve as the Chairman of the Audit Committee.

 

As a member of the Board, you will owe fiduciary duties to the Company and its stockholders, such as the duty of care, duty of loyalty and the duty of disclosure, which include protecting Company proprietary information from unauthorized use or disclosure.

 

The following summarizes the compensation that will be provided to you effective upon your appointment to the Board, and subject to approval by the Board:

 

●Cash Fees: Initially, your cash compensation will consist of $40,000 per year as an annual retainer fee for serving on the Board, and $10,000 per year for serving as the Chairman of the Audit Committee. It is contemplated that you will serve on one or more of the Compensation Committee, Strategic and Alternatives Committee and/or Nominating and Corporate Governance Committee, in addition to the Audit Committee. All such appointments are subject to the Board’s discretion. The Company will make fee payments one quarter in arrears, and will be pro-rated for partial quarters. The Company does not pay incremental fees for attendance of Board meetings or telephone/Zoom conferences but will reimburse you for reasonable travel expenses for attending in-person Board meetings and other Board-related expenses, subject to compliance with the Company’s reimbursement policies. You have the option of receiving half of your compensation in cash and half of your compensation in stock, or alternatively receiving all of your compensation in cash, with half of such cash compensation accrued until such time as the Company raises an aggregate of $1 million from any source (for greater certainty, such sources being cumulative and not discrete), including but not limited to debt and/or equity raises, quasi- equity raises, receipt of insurance proceeds, litigation proceeds, and corporate transactions.

 

 

 

 

 

The compensation set forth above is subject to change from time to time in the future as determined by the Board. In addition, the Company’s option plan outlines change in control provisions, termination rights, and other matters related to the option grants.

 

Enclosed are the following documents for your completion:

 

●Officers, Directors, Managers and Principal Stockholders Questionnaire and Supplemental Questionnaire for Director Nominees; and
   
●Policy on Insider Trading and Policy on Control and Disclosure of Confidential Information

 

This offer is submitted to you with the understanding that you will tender your resignation as a member of the Board in the event that you are not in compliance with the Company’s then applicable policies, codes or charters (including those set forth above). Should you accept this offer, you are representing to us that you (i) do not know of any conflict which would restrict your ability to serve on the Board and (ii) will not provide the Company with any documents, records, or other confidential information in violation of the rights of other parties.

 

Consistent with the Company’s governing documents, while the Board has authority to appoint you as a member of the Board, your continued service on the Board will be subject to stockholder approval at the next annual meeting of stockholders relating to the applicable Class of Directors to which you are appointed. Nothing in this offer should be construed to interfere with or otherwise restrict in any way the rights of the Company and the Company’s stockholders to remove any individual from the Board at any time in accordance with the provisions of applicable law.

 

You will also be entitled to indemnification for your services as a Board member in accordance with the Company’s standard form of indemnification agreement, a copy of which will be provided to you upon your appointment, and the governing documents of the Company.

 

You are free to end your relationship as a member of the Board at any time and for any reason. In addition, your right to serve as a member of the Board is subject to the provisions of the Company’s charter documents.

 

The terms in this letter agreement supersede any other agreements or promises made to you by anyone, whether oral or written, and comprise the final, complete and exclusive agreement between you and the Company regarding your service on the Board. Nothing in this letter should be construed as an offer of employment.

 

While you serve on the Board, you will be expected to notify the Company’s legal department of any conflicts of interests that may arise with respect to the Company.

 

I hope that you will accept our offer to join the Company’s Board of Directors and look forward to a productive future relationship. If you agree with the above, please indicate your agreement with these terms and accept this offer by signing and dating this letter below.

 

Sincerely,

 

/s/ James N. Woody  

James N. Woody, M.D., Ph.D.

 

Acknowledged and Agreed:

 

/s/ Omar Jimenez  
Omar Jimenez  

 

Date: March 4, 2024  

 

 

 

 EX-10.2 3 ea020144901ex10-2_180life.htm OFFER LETTER BETWEEN 180 LIFE SCIENCE CORP. AND RYAN L. SMITH (DIRECTOR) DATED MARCH 5, 2024 AND EFFECTIVE MARCH 7, 2024

Exhibit 10.2

 

 

March 5, 2024

 

Dear Ryan:

 

On behalf of 180 Life Sciences Corp., a Delaware corporation (the “Company”), I am pleased to extend to you an offer to join the Company’s Board of Directors (the “Board”), effective upon approval of your appointment by the Board of Directors. This offer is contingent upon (i) your completion of the enclosed Officers, Directors, Managers and Principal Stockholders Questionnaire and Supplemental Questionnaire for Director Nominees, (ii) receipt of a background check satisfactory to the Company, (iii) your confirmation of the enclosed Policy on Insider Trading and Policy on Control and Disclosure of Confidential Information, and (iv) formal approval of your appointment by the Board.

 

The Company’s current schedule includes approximately four regular meetings of the Board, which are currently held via Zoom, plus additional special meetings as called by the Board from time to time which usually take place via Zoom. In addition to your attendance at Board meetings, we expect to take advantage of your expertise by reaching out to you for advice and counsel between meetings. To the extent that you are appointed as a member of the Audit Committee, you will need to meet at least quarterly with the other members of the committee.

 

As a member of the Board, you will owe fiduciary duties to the Company and its stockholders, such as the duty of care, duty of loyalty and the duty of disclosure, which include protecting Company proprietary information from unauthorized use or disclosure.

 

The following summarizes the compensation that will be provided to you effective upon your appointment to the Board, and subject to approval by the Board:

 

●Cash Fees: Initially, your cash compensation will consist of $40,000 per year as an annual retainer fee for serving on the Board and $10,000 per year for serving as the Chairman of the Nominating and Corporate Governance Committee, and the Compensation Committee. It is contemplated that you will serve on one or more of the Audit Committee, and Strategic and Alternatives Committee. All such appointments are subject to the Board’s discretion. The Company will make fee payments one quarter in arrears, and will be pro-rated for partial quarters. The Company does not pay incremental fees for attendance of Board meetings or telephone/Zoom conferences but will reimburse you for reasonable travel expenses for attending in-person Board meetings and other Board-related expenses, subject to compliance with the Company’s reimbursement policies. You have the option of receiving half of your compensation in cash and half of your compensation in stock, or alternatively receiving all of your compensation in cash, with half of such cash compensation accrued until such time as the Company raises an aggregate of $1 million from any source (for greater certainty, such sources being cumulative and not discrete), including but not limited to debt and/or equity raises, quasi- equity raises, receipt of insurance proceeds, litigation proceeds, and corporate transactions.

 

 

 

 

 

The compensation set forth above is subject to change from time to time in the future as determined by the Board. In addition, the Company’s option plan outlines change in control provisions, termination rights, and other matters related to the option grants.

 

Enclosed are the following documents for your completion:

 

●Officers, Directors, Managers and Principal Stockholders Questionnaire and Supplemental Questionnaire for Director Nominees; and

 

●Policy on Insider Trading and Policy on Control and Disclosure of Confidential Information

 

This offer is submitted to you with the understanding that you will tender your resignation as a member of the Board in the event that you are not in compliance with the Company’s then applicable policies, codes or charters (including those set forth above). Should you accept this offer, you are representing to us that you (i) do not know of any conflict which would restrict your ability to serve on the Board and (ii) will not provide the Company with any documents, records, or other confidential information in violation of the rights of other parties.

 

Consistent with the Company’s governing documents, while the Board has authority to appoint you as a member of the Board, your continued service on the Board will be subject to stockholder approval at the next annual meeting of stockholders relating to the applicable Class of Directors to which you are appointed. Nothing in this offer should be construed to interfere with or otherwise restrict in any way the rights of the Company and the Company’s stockholders to remove any individual from the Board at any time in accordance with the provisions of applicable law.

 

You will also be entitled to indemnification for your services as a Board member in accordance with the Company’s standard form of indemnification agreement, a copy of which will be provided to you upon your appointment, and the governing documents of the Company.

 

You are free to end your relationship as a member of the Board at any time and for any reason. In addition, your right to serve as a member of the Board is subject to the provisions of the Company’s charter documents.

 

The terms in this letter agreement supersede any other agreements or promises made to you by anyone, whether oral or written, and comprise the final, complete and exclusive agreement between you and the Company regarding your service on the Board. Nothing in this letter should be construed as an offer of employment.

 

While you serve on the Board, you will be expected to notify the Company’s legal department of any conflicts of interests that may arise with respect to the Company.

 

I hope that you will accept our offer to join the Company’s Board of Directors and look forward to a productive future relationship. If you agree with the above, please indicate your agreement with these terms and accept this offer by signing and dating this letter below.

 

Sincerely,

 

/s/ James N. Woody 

James N. Woody, M.D., Ph.D.

 

Acknowledged and Agreed:

 

/s/ Ryan Smith  
Ryan Smith  

 

Date: March 5, 2024  

 

 

 

 GRAPHIC 4 ex10-1_001.jpg GRAPHIC begin 644 ex10-1_001.jpg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end GRAPHIC 5 ex10-2_001.jpg GRAPHIC begin 644 ex10-2_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BN8_P"$ MIF_Y]8_^^C72AAY8=L 8R?:M9TI0^(PI8BG5OR/8=17,W7B^.*8K;V_F(#C> MS8S]*U]*U:WU:!GBRKHIKCKKXAA)"+>PRG8R/@G\!TITZ%2I\*'5Q%.E\;-+Q!!NU-)K^&Z MGTY(ALCM\DB3/4@>W>H8/$4VD:;:VUY;7%UJ4Y9H[9!^\$>3MW>G%&E^,9M: MG2TL].(N#R[L^8XU[D]_PJ+4+N'0O&LFJ7KA;.6V2%I2I.Q\\ 8]ADUU*#_A MU(ZI;?UW_&QRN47^]IRT;WM_6WX7-C2?$4>IR_9Y;.XM+O+9AF7G ZGZ<@5M M5Q%E>PZ_\0(;_2MSVMK;-'<7&"%M=O7-7@H25E;3;L=5";E%W=]=^X M44@96) 8$CJ >E+6!N%%%% !1110 445&MQ"\A1)HV<=5# F@"2BBB@ HHHH M **** "BBB@ HHHH **** .5\3HJ74 50HV'H,=ZZ"[C:72YHT;:S1$ Y]JY MSQ<^VZM_=#_.M/Q'*\7AR4ID9"JQ'H2,UVM.4::/,BU&I6?];'+Z7JUKIT5P MEQ:"=I!A3Q^7TJ]X(B=KN[GR-@0)C/&M,TN]TR26Z1))MQ#;F^X.WT^ MM9?AF00^,'@M9"]N?,7/]Y1T/\JZJCC*-2,=^IRT8RA*E*5K=!WB>:;5_%,. MEH^(T98U'8,>2WY?RKLK#1=/TZV6&&VC.!\SLH+,?4FN&\4>=HGC"+4@A:-V M65?]HCAE^O\ C7HT,HG@CE"LH=0P5A@C/J*YL0VJ4.7:WXG;ADG5J.7Q7_ X M?QPMUHMO#=:4D=I \H:=X1M8N/NY_P!GK^-=)H6HP^(O#]O=2Q(WF#$L;+D; MAP>#6)\2-0@M_#9LV=?/N'78G? .2?T_6K'P\MI+?PC T@(\Z1Y5!_NDX'\J M,1PQ)$@_A10H_(5)117 =YS/AW_D8M>_Z[ M#^M;]ZS)87#*2&$3$$=C@UQ]GK-OHWB#63?\( MS]JF^T>:!YF M\[L;O6K5K9QL8'/BJ8L2I,9F')].M9AS_P *V7@Y\X?^A5U-IX?TD002_8(/ M,VJV[;SG&B[F/J\LLOBP6C:I-96Y@#;EDVC/X\5K:+;Q MPSRE-:DU#*@%&D#;.>O%86MR6,/C+?J47F6WV< KLW<]N*V= N=$GN)ETJW\ MJ0*"Y\LKD9XJ)I^S5ET[+_ARX->T=^_G_P ,3^)_M7_"/W/V/=YF!G9UVYYQ M^%8FBZ;X;OX[9K>1ENX\,RF0J[,.N1W'TKJ-1O?[/L9+GR)9]G\$8R37$ZQ> M:9JPA.E6577FOU"MRJ5WKY?Y&]KVI7K:A;Z/IC!+F M<;GE/\"_Y!J!O#VL6@6>RUJ:6X!&Y)ON-Z^M)K,%YIVIV6N11&?RXO+N47KC MN1^=/E\:6LB*EA;7%Q9^T=GT_P" /UFYNH?$ M&B0K.ZK(V)50D*_3M5"[DDN?%5];2ZQ-8P1HK)B3:,X''-6M<+/XDT!BA4ER M2I[=.*S;Z;3(/&&H-JL/FPE%"#86PV!_2KIK1:='^9-1ZOU_0WK&);;3[YHM M7DOSY9.YI WED ],?YXK&\*:Y=+.EKJ$LCI=#=!+(<_,.",_Y_6M73KC2)], MU'^R8/* C/F?NRN3M.*R]-TG^U?!,"Q_+=0N[PMT(;<>/QJ5:TE/JU\M!N]X MN/9FEX?O)GO];^T3N\<,_P H9LA!\W2J5JNI^*GENOMTEE8!RL21=6QW-)X- M$ETNKBYR))6429&#DALTW2]4/A<2:7JD,BQ*Y:&9%R&!IN+4IT*3LJH9@,C\371:5 MK_\ :]](EO9RBT1>+AQ@%O3%;*;ABA,1;"T04O>YEKILD$ MW'W;/37>YT5]<3Z7X3EEL[U[QP<"X)#$ GD_A571-/DN&MKRW\0S3'AIXB>>/2N6N9M.GU&SD\.Q3Q7ID&Y I"@> M_P#G&*()M-6MYV7X]@FTFG>_EK^!U6MZ'+JL\4D-EVL/6I:*Y'4DTEV.A4H*3DEON<1=^!;@S-]DO4$1[2 @@>G'6MS0/#<& MB(S[_.N7&&D(P /0"MNL+Q3JUSIEC!'9!?M=W,L$3-T4GO6_MJM:U.^YA]7H MT;U$MOZT+&O@M9H(; 7MV'#6Z,ORHX_B)/0"N#DC\?:?(Z1_:I-[%BR%9%R? M3/2MK4!K7A6V749]9FOHF(CEC>,;4+'&[KT'^%=LK!D# Y!&0?6M(U/8QT2D MGZDNG[:6K<6O0\OTSP+J^LZB+WQ%*Z1Y!97?=)(/3CA17I\4:0Q)%&H2- %5 M0. !T%.HK"M7G6:YMET-Z-"%)>[N^H4445@;ABC HHH ;L7;MVC'IBG444 - M*(QR5!/N*4(J_=4#Z"EHH *:$522% )ZD"G44 %,6*-&++&JD]2!C-/HH 0J M"02 2.AI#&A.2BD^XIU% "!%4$!0,^@H "C ]J6B@! H!) SUQ2.B2+M= M58>A&:=10 BJ% "@ #H!2>7'_<7\J=10 @ 48 'M35BC1BR(JD]2!C-/HH M**** "LGQ!HYUFRCA5E5HI!*I;(Y .!D=.<9]JUJ*J,G%\R)E%27*SB+G2O% M/B%8;'6!9VU@CAYF@;+38[ =J;#XKU)+3^UY$M!IAG^SQVBY\_[^P').,]3C M%=S7 3VMNWQ3MU:"(J(BX!08##H?K[UVTIJI=2BK)7T_'[^YQU(.G9Q;NW;_ M "^[L=_1117 =P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 ,0 4444 %%%% '__9 end EX-101.SCH 6 atnf-20240307.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 7 atnf-20240307_def.xml XBRL DEFINITION FILE EX-101.LAB 8 atnf-20240307_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants to purchase shares of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 9 atnf-20240307_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 07, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2024
Entity File Number 001-38105
Entity Registrant Name 180 LIFE SCIENCES CORP.
Entity Central Index Key 0001690080
Entity Tax Identification Number 90-1890354
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3000 El Camino Real
Entity Address, Address Line Two Bldg. 4
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94306
City Area Code 650
Local Phone Number 507-0669
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ATNF
Security Exchange Name NASDAQ
Warrants to purchase shares of Common Stock  
Title of 12(b) Security Warrants to purchase shares of Common Stock
Trading Symbol ATNFW
Security Exchange Name NASDAQ
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://180lifesciencescorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports atnf-20240307.xsd atnf-20240307_def.xml atnf-20240307_lab.xml atnf-20240307_pre.xml ea0201449-8k_180life.htm http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0201449-8k_180life.htm": { "nsprefix": "ATNF", "nsuri": "http://180lifesciencescorp.com/20240307", "dts": { "schema": { "local": [ "atnf-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "atnf-20240307_def.xml" ] }, "labelLink": { "local": [ "atnf-20240307_lab.xml" ] }, "presentationLink": { "local": [ "atnf-20240307_pre.xml" ] }, "inline": { "local": [ "ea0201449-8k_180life.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://180lifesciencescorp.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201449-8k_180life.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201449-8k_180life.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "auth_ref": [] }, "ATNF_CommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciencescorp.com/20240307", "localname": "CommonStockParValue0.0001PerShareMember", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciencescorp.com/20240307", "localname": "WarrantsToPurchaseSharesOfCommonStockMember", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of Common Stock" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://180lifesciencescorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0001213900-24-021213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-021213-xbrl.zip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ea0201449-8k_180life_htm.xml IDEA: XBRL DOCUMENT 0001690080 2024-03-07 2024-03-07 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-03-07 2024-03-07 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-03-07 2024-03-07 iso4217:USD shares iso4217:USD shares false 0001690080 8-K 2024-03-07 180 LIFE SCIENCES CORP. DE 001-38105 90-1890354 3000 El Camino Real Bldg. 4 Suite 200 Palo Alto CA 94306 650 507-0669 false false false false Common Stock, par value $0.0001 per share ATNF NASDAQ Warrants to purchase shares of Common Stock ATNFW NASDAQ false